Zydus and Torrent Pharma to co-market Semaglutide injection in India

Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device

Zydus Lifesciences and Torrent Pharma have teamed up to co-market Semaglutide Injection in India. Under this licensing and supply deal, Zydus will handle manufacturing and supply, while Torrent Pharma gains semi-exclusive rights to market the drug under its own brand, SEMBOLIC.

Zydus will sell the injection under the brands SEMAGLYN, MASHEMA, and ALTERME. In return for these rights and Zydus's manufacturing support, Torrent Pharma will pay an upfront licensing fee, leveraging its extensive distribution network to reach patients nationwide.

Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable patient-friendly pen device, enabling delivery of all strengths for both indications through a single device platform. The formulation combined with the reusable pen device is designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance, addressing key challenges in chronic disease management.

It is also indicated for use in adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidaemia.

This partnership brings together Zydus's strong product development and manufacturing capabilities and Torrent Pharma's deep market expertise across India, with the shared objective of improving patient access to advanced GLP-1 therapies for metabolic disorders.